Markets
markets
Luke Kawa

Stocks little changed after Federal Reserve signals rate cuts to come as growth slows while inflation rises

US stocks stayed largely flat after the Federal Reserve kept rates in a range of 4.25% to 4.5%, as was universally expected, and cut its growth forecast while boosting the outlook for inflation.

The central bank also put out its so-called “dot plot,” which lays out officials’ views on where policy rates will go if the economy unfolds according to their expectations (obviously, a big “if”). The median policymaker thinks 50 basis points of easing will be delivered this year, the same as in March, but now sees less easing to follow in 2026.

Traders were pricing in about 46 basis points of easing through year-end heading into the decision.

A survey performed by Macro Policy Perspectives showed that Fed watchers were roughly split between those who expected the dot plot to signal the median official anticipated one or two cuts this year.

More Markets

See all Markets
markets

IREN drops on convertible debt offering

Shares of crypto miner and AI compute provider IREN dropped after the Australia-based, US-listed company said late Tuesday that it would sell $875 million in convertible senior debt.

The announcement came late in the trading day and caused a sell-off in the aftermarket session that continued into Wednesday trading.

The offering makes sense; the company can probably get some fairly cheap capital after its shares doubled over the last month.

But it exposes shareholders to some dilution risk if buyers of the hybrid securities do convert them into equity, which explains the market reaction.

The offering makes sense; the company can probably get some fairly cheap capital after its shares doubled over the last month.

But it exposes shareholders to some dilution risk if buyers of the hybrid securities do convert them into equity, which explains the market reaction.

markets

Tempus AI shares surge to all-time high

Shares of Tempus AI jumped over 7% Wednesday to reach an all-time high of $99.90. Shares of the AI medical diagnostics company are up over 191% for the year so far.

The company has recently announced a flurry of FDA clearances for its technologies. Most recently, on September 22, Tempus AI was granted FDA clearance for its Tempus xR IVD device, which is used to tailor cancer therapies.

Latest Stories

Sherwood Media, LLC produces fresh and unique perspectives on topical financial news and is a fully owned subsidiary of Robinhood Markets, Inc., and any views expressed here do not necessarily reflect the views of any other Robinhood affiliate, including Robinhood Markets, Inc., Robinhood Financial LLC, Robinhood Securities, LLC, Robinhood Crypto, LLC, or Robinhood Money, LLC.